Verastem Inc (VSTM) is a Healthcare · Biotechnology company listed on NASDAQ. Price $7.44 (-1.46%), Market cap $0.43B, 52-week low–high $4.15 ~ $10.77.
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the
Financial statements, price targets, institutional (13F) holdings and related news for Verastem Inc are updated in real time on BlackAll Trade.
Verastem Inc trades at $7.44 (-1.46%). Real-time quotes and charts are available on BlackAll Trade.
Verastem Inc has a market cap of about $0.43B.
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib